Obsidian Therapeutics (OBX) news
Recent news
OBSidian Therapeutics, Inc: Leerink Partners initiates coverage with outperform rating; target price $32
Leerink Partners has initiated coverage of Obsidian Therapeutics, Inc. (NASDAQ: OBSN) with an "outperform" rating and a target price of $32 per share, as reported on September 22, 2026. The firm's decision follows a review of the company’s recent developments and strategic positioning in the…
AInvest Wire · Sep 22, 2026Obsidian Therapeutics - Files prospectus relates to resale of up to 29,164,045 shares of common stock by selling stockholders - SEC filing
Obsidian Therapeutics, Inc. (OTC: OBX) has filed a prospectus with the U.S. Securities and Exchange Commission (SEC) related to the potential resale of up to 29,164,045 shares of its common stock by selling stockholders. The filing, which is part of a registered offering under Form S-8, outlines…
AInvest Wire · Aug 28, 2026RTW Biotech Opportunities - Obsidian completes merger with Galera
AInvest Wire · Aug 5, 2026RTW Biotech opportunities - combined company trades on Nasdaq under ticker "OBX" after $350 mln private financing
AInvest Wire · Aug 5, 2026RTW Biotech Opportunities - Obsidian Therapeutics merges with Galera
AInvest Wire · Aug 5, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.